UK drugs watchdog NICE has published its finance guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS through the Cancer Drugs Fund for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy. The decision makes the drug the first and only immunotherapy to be approved for use on the health service by the agency.
Original Article: NICE recommends Keytruda via CDF as first and only urothelial carcinoma immunotherapy
NEXT ARTICLE